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Abstract 
Vaccinia virus (VACV) is well known for its use as the vaccine in the 
successful campaign to eradicate smallpox and a powerful vector for vaccines, 
immunotherapies, and oncolytic viral therapies. Advancements in synthetic 
biology have recently led to the development of synthetic gene circuits, which 
can use recombinases to respond to inputs with logic and memory. We propose 
that this technology can be employed to make “logical” VACV vectors which 
could be programmed to change their actions based on sensory inputs for use in 
the development of safer vaccines or oncolytic viral therapy agents which 
selectively lyse cancer cells. In this project we tested the functionality of 
recombinases Bxb1 and PhiC31 in synthetic VACV circuitry. We developed 
simple synthetic circuits with VACV promoters wherein each recombinase can be 
induced under lac or tet operon elements to irreversibly invert a promoter, which 
switches fluorescent reporter expression from red to green and can be observed 
in VACV infection/transfection assays. We detected only red fluorescence with 
little to no green in cells transfected with bxb1 plasmids, suggesting that no 
promoter inversion occurred and Bxb1 may not be functional in VACV-infected 
cells. Green fluorescence indicative of promoter inversion was detected in all 
cells transfected with phiC31 plasmids. This occurred regardless of absence of 
inducer, suggesting PhiC31 is highly functional in VACV-infected cells but cannot 
be regulated by TetR or LacI repressor proteins, even when they are pre-
expressed at high levels. Future recombinase-based synthetic circuitry in VACV 
will thus require tighter repressor systems.   
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INTRODUCTION 
 
Vaccinia Virus Overview 
Vaccinia virus (VACV) is a large, enveloped, double-stranded DNA virus 
prototypical of the family Poxviridae and the genus Orthopoxvirus.  The VACV 
infectious cycle begins with attachment and entry of a virion into a susceptible 
cell. Entry occurs by fusion of the viral lipid membrane to the cell membrane, 
releasing the core into the cytoplasm (1), where replication occurs (2). 
Transcription is divided into early, intermediate, and late stages. Early 
transcription is coupled to the replication of the viral genome (3), which once 
completed proceeds to intermediate and late stages when genes for the 
synthesis of proteins for new viral particles are transcribed (4). Transmission of 
VACV between cells can take place by spread of intracellular mature virus after 
cell lysis, movement of cell-associated enveloped virus on actin tails to adjacent 
cells, and by extracellular enveloped virus traveling to proximate or distant cells 
(5).  
 
Applications of Recombinant Vaccinia Virus Vectors 
VACV was employed as the vaccine in the World Health Organization 
campaign to eradicate smallpox (6). As a result, the scientific community has 
extensive understanding of VACV. The VACV genome can accommodate over 
25 kilobases (kb) of exogenous DNA (7), and such “recombinant” VACVs are 
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excellent expression vectors in eukaryotic cells. Additionally, recombinant VACVs 
have been shown to elicit strong humoral and cell-mediated immune responses 
both for vaccine and oncolytic therapy applications (8, 9). By expressing 
exogenous antigens, a recombinant VACV can train the immune response 
against different pathogens. Recombinant VACV vectors have accordingly been 
used extensively as both human and animal vaccines (10), including oral rabies 
vaccines for wildlife (11-13) and recently, promising HIV vaccines (14, 15). VACV 
has also been used for cancer vaccines, eliciting an immune response against 
cancers by expressing tumor-associated antigens (16). VACV has also shown 
great potential as an agent for oncolytic viral therapies since it can replicate in 
many mammalian tissues and destroys tumors both directly by virus-mediated 
cytotoxicity and by inciting the host cell-mediated effector immune response (17). 
Additionally, it has also been implemented in tumor-directed gene therapies, 
wherein viruses are targeted specifically to tumor cells and used to express 
enzymes which interact with prodrugs administered to the patient, increasing 
cure rate and prolonging survival (18).  
The clinical use of these VACV-based therapies is limited by 
complications due to uncontrolled viral replication ranging from mild rash and 
fever, to rare but severe adverse reactions. These are usually limited to 
individuals with pre-existing susceptibilities, such as eczema in the case eczema 
vaccinatum and immune deficiency in the case of progressive vaccinia (19). As a 
result, many researchers have elected to use replication-deficient or attenuated 
VACV strains such as Modified Vaccinia virus Ankara (MVA) (20). However, 
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interest in using replication-competent and more immunogenic strains such as 
Western Reserve (WR) has prompted the development of regulatory systems for 
the situational control of vaccinia gene expression and replication, including 
inducible systems using elements of the lac or tet operons, and a repressible 
system using a reverse tet repressor (Hagen, Jasperse and Titong, unpublished), 
(21-23).  
 
Lac and Tet Operons 
 The lac operon is the prototypical bacterial gene regulatory unit and its 
discovery and characterization are of great historical importance in molecular 
biology (24). Originally described by Jacob and Monod, it was the basis for the 
understanding of bacterial gene regulation, wherein the protein products regulate 
the expression of genes at the level of transcription depending on environmental 
conditions (25). In the lac operon, “structural genes” including β-galactosidase 
and a lactose transporter are downstream of an operator sequence, to which the 
lac repressor protein LacI binds, preventing transcription in the absence of the 
metabolite allolactose (26-28). An artificial analog for allolactose developed by 
Monod, 1-isopropyl-β-d-thiogalactoside (IPTG), can be used as a gratuitous 
inducer of the lac operon (26). 
 The tet operon was also discovered in Escherichia coli, in which the 
expression of TetA, a transporter protein enabling resistance to tetracyclines, is 
regulated analogously to the lac operon; repressor protein TetR binds tightly to 
the tetO operator sequence in the absence of tetracyclines, preventing 
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expression of tetA, but in the presence of tetracyclines a conformational change 
takes place which decreases affinity of TetR for the operator and allows for tetA 
transcription (29, 30). This regulatory system has been extensively used as a 
transactivator in both prokaryotes and eukaryotes to regulate both endogenous 
and transgene expression (31-33). Both the lac and tet repressor systems have 
been previously characterized in VACV vectors (22, 34, 35).  
 
Applications of Current Tools in Synthetic Biology 
 Synthetic biology is a rapidly evolving field that is generally defined as the 
design and construction of novel biological systems or the re-design of existing 
biological systems to solve problems. In the former category, synthetic biologists 
develop artificial biomolecules which parallel known ones in the interest of 
creating artificial life, which although popular, exciting, and promising, is not the 
aim of our project and will not be discussed here (36). In the latter, scientists 
draw on a body of scientific knowledge about components of different biological 
systems and integrate them in various degrees of complexity to engineer a 
biological design (37). This technology can be used to assemble biological 
pathways for the synthesis of industrially important chemicals (38).  
Of particular interest to us are synthetic regulatory gene networks. We 
believe that if VACVs could be developed with complex artificial regulatory 
systems that can interact with their environment, they would have myriad 
potential uses in medicine and research. Using well-studied and standardized 
5 
 
genetic elements, over the past decade and a half synthetic biologists have 
developed numerous varieties of genetic circuit elements capable of responding 
to environmental inputs. Using a pair of promoters and repressors, Gardner et al. 
developed a bistable genetic toggle switch to control gene expression (39). 
Transcriptional regulatory systems have also been built to oscillate on a 
timescale different from their host organism’s replicative processes, allowing the 
state of the synthetic gene circuit to be transmitted and self-maintaining through 
generations (40). The implementation of recombinases, enzymes which catalyze 
the excision, inversion, and reinsertion of a target DNA sequence (41) in 
synthetic biology, or “recombinatorics”, has opened the door to the development 
of computer-like logic in synthetic biology (42). At the simplest level, these 
recombinases catalyze irreversible inversions and allow for strict regulation of an 
inducible expression system (43). It is also possible to use recombinases that 
catalyze reversible inversion in conjunction with excisionases to create rewritable 
memory systems inside the genetic code of living cells (44). These technologies 
have demonstrated usefulness in bacterial and viral vectors with practical 
medical applications, including the engineering of bacteria to invade cancer cells 
or to destroy biofilms and thus serve as adjuvants for antibiotic therapies (45, 
46). An excellent review on the current accomplishments and obstacles in the 
field of synthetic gene networks was written by Lu et al (47). Recently, Siuti et al. 
used recombinase-based synthetic gene circuitry to implement the sixteen 
Boolean logic gates in E. coli using two recombinases under different inducible 
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systems to integrate two signals into one logical output with “memory” which 
lasted through bacterial generations (48).  
 
Bxb1 and PhiC31 Recombinases 
 For this project we sought recombinases that could carry out a 
unidirectional, irreversible inversion of a DNA segment flanked by recognition 
sequences specific to that enzyme, such that if a multi-recombinase logic system 
were ever developed, there would be no cross-reactivity between one 
recombinase and the recognition sites of another. Bacteriophage large serine 
recombinases catalyze viral integration by acting on a specific site on the viral 
genome (attP) and another on the host chromosome (attB), but can also catalyze 
the inversion of DNA segments resulting in gene expression (49). They do this by 
binding the DNA segments, cleaving them, repositioning their ends by subunit 
rotation, and ligating the segments together (50). We selected two large serine 
recombinases, Bxb1 (51) and PhiC31 (52) for use because they both have been 
thoroughly characterized (53), used by genetic engineers in eukaryotes (53-55), 
and were used by Siuti et al. in their Boolean logic circuits project (48), 
suggesting that there is no cross-reactivity between them and that they can be 
expressed as transgenes in eukaryotic cell lines.  
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Hypothesis 
Recombinase-based synthetic gene circuits stand to greatly increase the 
potential uses and safety of VACV vectors. Because the VACV genome can 
accommodate 25 kb of exogenous genetic material, recombinant VACV vectors 
theoretically could be produced with multiple foreign or natural genes under a 
complex multi-recombinase regulatory system. We hypothesize that 
recombinase-based gene circuit regulation is possible in VACV. Because VACV 
replicates in the cytoplasm using its own transcriptional machinery, it is not 
possible to create a recombinant VACV with recombinase logic using existing 
synthetic circuitry because at the time of this paper none have included VACV 
promoters. The goal of this project was to demonstrate that recombinase-based 
regulation in a simple genetic circuit is possible in VACV. In the interest of 
ultimately building circuits with binary inputs, we sought to test two 
recombinases. We placed them under the control of a weak VACV promoter and 
inducible operator so their expression could be controlled by the administration of 
inducer molecules doxycycline (Dox) or IPTG. A reporter cassette was generated 
with a red and green fluorescence reporter on either side of a strong vaccinia 
promoter flanked by recombinase recognition sequences. If repression of 
recombinase activity with VACV transcription machinery is sufficient, then only 
red fluorescence reporter is produced. Induction of the recombinase results in 
inversion of the promoter, cessation of red fluorescence reporter expression and 
transcription of green fluorescence reporter (Figure 1).  
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MATERIALS AND METHODS 
 
PCR of Recombinase Genes 
Two recombinases (Bxb1 and PhiC31) and their recognition sites (53), 
were selected for use in our experiments on the basis of their previous use in 
mainstream synthetic biology projects with similar circuitry. phiC31 was obtained 
from plasmid “pInt” (56) and bxb1 was obtained from plasmid “Dual-
Recombinase Controller” (57), both from Addgene (Cambridge, MA). 
Recombinase genes were PCR-amplified so that the final products would have 5’ 
and 3’ restriction sites to facilitate cloning into a vector backbone. Forward 
primers overlapped with the translation start site and included a 5’ spacer (6 bp) 
and restriction enzyme recognition site immediately preceding the start codon. 
Reverse primers overlapped with the sequence complementary to the 3’ end of 
the gene and included a 5’ spacer (6 bp) and restriction enzyme recognition site 
immediately preceding the complement of the stop codon.   
 
Logical Circuit Plasmids 
A vector backbone was synthesized to enable subcloning of red 
fluorescent reporter DsRed and green fluorescent reporter EGFP, recombinase 
bxb1 or phiC31, and repressor gene tetR or lacI. Vector backbones were 
synthesized by a third party vendor DNA 2.0 (Menlo Park, CA) as high copy 
plasmids with a kanamycin resistance gene. Spacers of 25 bp from ampR were 
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included between restriction enzyme cut sites. Promoters were chosen based on 
the desired level of expression for each gene. Because even minimal expression 
of a recombinase could result in inversion of our target promoter, we sought to 
maximize expression of our repressor genes and have minimal but sufficient 
levels of expression of our recombinase when unrepressed. We also selected 
promoters with minimal sequence similarity to one another in order to avoid 
unwanted recombination events. We chose synthetic promoter PE/L, the strongest 
known VACV promoter, for expression of lacI and tetR. The strong cowpox 
promoter PATI, as previously modified by the Verardi Lab (23), was selected for 
reporter gene expression. P5, a weakened version of late promoter P11 (23) was 
chosen to drive recombinase expression. Restriction enzyme sites were selected 
based on the availability of genes from plasmids and enzymes in the Verardi Lab 
in order to minimize the need for PCR cloning and minimize the use of enzymes 
that would cut within the final transfer vector. Vector pPL189 was synthesized 
with recombinase recognition sites bxb1 attB/attP for use with bxb1 under control 
of the lac operon (Figure 2A). Vector pPL190 was synthesized with recombinase 
recognition sites phiC31 attB/attP for use with phiC31 under control of the tet 
operon (Figure 2B).  
Inserts were cloned into vector backbones in parallel. Unless otherwise 
stated, plasmids were obtained from the Verardi Lab and enzymes were obtained 
from New England Biolabs (Ipswich, MA). Genes encoding respective repressor 
proteins were subcloned into the vector backbones first. The lacI-wf gene is a 
W200F mutant lacI that has been shown to produce a repressor with a 10-fold 
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greater decrease in leaky transcription (58). Our lab had previously synthesized 
lacI-wf with mutation in a TTTTNT to prevent early transcription termination by 
VACV transcriptional machinery. For cloning, lacI-wf was cleaved from pCO157 
with PstI-HF and blunt cutting restriction enzyme SmaI and cloned into pPL189 
cleaved with PstI-HF and blunt cutting restriction enzyme ScaI-HF to create 
pPL193. The tetR gene was obtained from pSMART10 because that version of 
the gene was also synthesized to lack a VACV terminator sequence TTTTTNT 
present in the wild type gene (14). pSMART10 was cleaved with SphI-HF and 
SmaI and cloned into pPL190 cut with SphI-HF and ScaI-HF to create pPL192 . 
EGFP was cloned into pPL192 and pPL193 from pCO191 with SacI-HF and 
NcoI-HF to create pPL194 and pPL195. DsRed was cloned into pPL194 and 
pPL195 from pCO191 with SpeI and NotI-HF to create pPL196 and pPL197. 
Recombinases were cleaved from their PCR amplicon into pPL196 and pPL197 
with MfeI-HF and NotI-HF to create pPL198 and pPL199 for transient expression 
assays in VACV-infected cells (Figure 2C-D). To isolate the variables of each 
inducible system and recombinase, we then generated two more plasmids; in 
pPL200 bxb1 is under control of the tet operon, and in pPL201 phiC31 is under 
control of the lac operon. This was accomplished by digesting pPL198 and 
pPL199 with MfeI-HF and KpnI-HF and swapping out the inserts and vectors 
(Figure 2E-F).  
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Gene Cloning 
Inserts were double digested from plasmids or PCR amplicons in the case 
of the recombinases, and vectors were double digested to remove spacers with 
restriction enzymes to create mutually compatible cleavage sites for directional 
cloning. Note that in the digestion of pPL198 with MfeI-HF and KpnI-HF, the 
insert and vector were of indistinguishable size, so to facilitate gel purification it 
was also incubated with NdeI or EagI-HF, digesting the unwanted fragment into 
smaller pieces. Vectors were dephosphorylated by incubation with Antarctic 
Phosphatase. Inserts and vectors were ligated with T4 DNA ligase and 
electroporated with a Gene Pulser Xcell Electroporation System (Bio-Rad, 
Hercules, CA) into NEB 5-alpha Electrocompetent E. coli (New England Biolabs), 
The electroporated suspension was plated onto low-salt LB agar plates with 50 
µg/ml kanamycin and incubated for 16 hours at 37°C. Twenty well-isolated 
colonies were miniprepped and the DNA was evaluated for desired ligation and 
transformation results by diagnostic restriction enzyme digest and 
electrophoresis in an agarose gel containing ethidium bromide visualized by 
ultraviolet excitation. One culture verified to contain the desired plasmid was 
grown for a larger scale DNA isolation and use in subsequent cloning reactions. 
DNA isolation and purification was performed using a NucleoSpin® Plasmid kit 
(Macherey-Nagel, Bethlehem, PA). pPL198, pPL199, pPL200, and pPL201 were 
grown up, isolated, and purified on a larger scale using a NucleoSpin® Midiprep 
kit (Macherey-Nagel).  After large scale-preparation with a commercial kit, 
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plasmids were reanalyzed with a restriction-enzyme digest and compared with 
the original vector to verify the identity of the product. 
 
Cell Culture 
 African Green Monkey kidney epithelial cells (BS-C-1) and human HeLa-
S3 cells were grown in adherent culture with Dulbecco’s modified Eagle medium 
supplemented with glucose and amino acids (Invitrogen, Grand Island, NY) 
(cDME) and containing 10% fetal bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA) at 37 °C in 5% CO2 as described previously (22).  
 
Viruses 
 L-variant Western Reserve (WR) VACV ATCC clone 9.2.4.8. (22) was 
used as our wild-type VACV strain and was previously amplified in HeLa-S3 
cells, purified, and titered in BS-C-1 cells by the Verardi Lab. vP11IRG was 
previously developed, purified and amplified by our lab (Titong, Jasperse, Verardi 
unpublished data). It was generated by homologous recombination of plasmid 
pSP114 with the VACV thymidine kinase region. It contains tetR under a PE/L 
promoter, lacI under P11 and a tet operator, and EGFP under another P11 and a 
lac operator; so in the presence of Dox LacI is produced, preventing expression 
of EGFP.  vS22 is a previously developed VACV (vPE/L-Control) that expresses 
tetR constitutively under the PE/L promoter (21).   
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Transient Expression Assays 
  BS-C-1 or HeLa-S3 cells were seeded in 24 or 48-well cell culture plates 
to be 95% confluent at the time of the experiment. VACV stocks were sonicated 
in four 30-second bursts, vortexed between bursts, and diluted to achieve an 
MOI of 1 based on the desired infection volume and estimated number of cells 
per well. Cells were washed once with cDME, overlayed with virus dilution, and 
incubated for 1 hour post-infection during initial testing and 24 hours for 
subsequent testing when we wanted to pre-express LacI and TetR in vS22 and 
vP11IRG infected cells. Cells were then overlaid with cDME supplemented with 
2.5% FBS +/- 1 mg/ml Dox or 1 mM IPTG and transfected with desired plasmids 
using FuGENE HD transfection reagent (Promega, Madison, WI). Cells were 
incubated at 37 °C in 5% CO2. Results were obtained by fluorescence (Texas 
Red filter for DsRed and FITC filter for EGFP) and brightfield microscopy at 24, 
48, and 72 hours post transfection using an Axio Observer D1 inverted 
fluorescence microscope (Carl Zeiss, Thornwood, NY). Images were captured 
using AxioVision software, release 4.8.1 (Carl Zeiss).  Representative images 
were taken.  
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RESULTS 
 A pilot transient expression assay was performed in BS-C-1 cells using 
pPL198 and pPL199. Cells were infected with WR for one hour prior to 
transfection. 48 hours post transfection (p.t.), all wells transfected with pPL198 
exhibited green fluorescence at similar levels to the transfection control with no 
detectable red fluorescence, which persisted for the course of the experiment. 
(Figure 3). Red fluorescence was detected in pPL199-transfected wells (Figure 
3A) at levels similar to the transfection control (Figure 3C). After 72 hours, small 
amounts of green fluorescence were observed in the pPL199-transfected wells 
both with and without IPTG, which otherwise exhibited red fluorescence similar to 
transfection control levels (Figure 3B).  
 During the pilot experiment we observed that at 48 and 72 hours post 
infection, data collection became increasingly difficult due to the number of BS-C-
1 cells that lysed or lost adherence to the plate, so subsequent assays were 
performed in HeLa-S3 cells. In order to confirm that the results of the pilot 
experiment were not due to improper insertion of fluorescent reporter genes or 
promoter inversion prior to transfection, we reanalyzed the placement and 
orientation of the recombinases in the plasmids via a different restriction digest 
and PCR, confirming our original determination that the plasmids were as 
designed.  
 Next we tested pPL198, pPL199, pPL200, and pPL201 (Figure 2) in HeLa-
S3 cells infected with WR. To control for the possibility that in the first experiment 
PhiC31 was synthesized before sufficient repressor was produced to modulate 
15 
 
expression, we also tested tet operator plasmids pPL198 and pPL201 in cells 
infected with vS22, a recombinant VACV that constitutively expresses TetR, and 
lac operator plasmids pPL199 and pPL200 in cells infected with vP11IRG, a 
recombinant VACV that constitutively expresses LacI. Because vP11IRG 
expresses EGFP in a tetracycline-repressible fashion, cells infected with it were 
overlaid with media containing 1 mg/ml Dox, previously shown to repress EGFP 
expression to levels indistinguishable from WR (Titong et al., unpublished data).  
Our vP11IRG control (no plasmid transfected) results were consistent with this at 
24 hours post infection (Figure 4A), however after 48 (Figure 4B) and 72 hours 
(Figure 4C), we noticed a few cells (less than 10 in a well of ~9.4x104 cells) with 
green fluorescence, suggesting that this virus may undergo mutation to 
constitutive EGFP expression. We also noted after 72 hours a detectable amount 
of EGFP fluorescence localized to every cell (Figure 6D), suggesting that a small 
amount of expression had occurred. These findings limit the power of our results 
from vP11IRG-infected cells.  
The HeLa-S3 cells did maintain a better monolayer for fluorescence 
imaging than the BS-C-1 cells, even when infected with VACV, but once again 
we never observed any difference between groups with or without inducer 
(Figure 5). Cells infected with WR and transfected with pPL198 (Figure 5A) or 
pPL200 (Figure 5B) exhibited green fluorescence similar to the level of the 
transfection control (Figure 5E), with no detectable red fluorescence. This was 
also true for cells infected with rVACVs vS22 and vP11IRG to pre-express 
repressor proteins TetR and LacI respectively (Figure 5C-D). These data suggest 
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that PhiC31 is functional in our VACV synthetic circuitry, but it cannot be 
controlled by the lac or tet repressor systems.  
Cells infected with WR and transfected with pPL199 (Figure 6A) or 
pPL201 (Figure 6B) exhibited red fluorescence at levels similar to the 
transfection control, with no detectable amount of green fluorescence. This is 
also true for cells infected with vS22 and transfected with pPL201 (Figure 6C). 
We did find a few green fluorescent cells in wells infected with vP11IRG and 
transfected with pPL199 (Figure 6D), however these were at levels 
indistinguishable from the vP11IRG control (Figure 6E), and this was not 
detected in cells infected with WR (Figure 6A), suggesting that this is more likely 
a result of vP11IRG mutation than Bxb1 activity. Taken together, these results 
support the conclusion that PhiC31 can function in VACV synthetic circuitry but is 
irrepressible by the tet operon, and that our Bxb1 is not functional in our VACV 
synthetic circuitry.  
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DISCUSSION 
 The implementation of reliable invertase-based logic gates or more 
complex logical circuitry in VACV vectors could greatly enhance their usefulness 
in both research and medicine. Eventually, VACVs could be engineered in which 
recombinases are inducible by well-studied cellular signals or transcription 
factors, either host-derived or exogenous genes carried by the virus. In oncolytic 
viral therapy, for example, important tumor suppressors such as p53 (59) or one 
of its downstream effectors could be considered an indicator of non-cancerous 
cells and accordingly used as an inducer of a recombinase that alters VACV 
circuitry in such a way that inhibits VACV replication. The reverse could be done 
with known oncogenes. Such an oncolytic VACV therapy would have to be 
specifically designed for a particular type of tumor. Such vectors could also 
include control switches allowing them to be induced or repressed within patients 
with drugs. Inducible (60) and repressible (Jasperse, O’Connell, Titong, Verardi, 
unpublished data) systems have already been shown to be efficacious in 
controlling VACV gene expression in vivo. Similarly, VACVs could be engineered 
to shut off essential gene expression in response to an adverse reaction. For 
example, patients with atopic dermatitis are susceptible to developing eczema 
vaccinatum. During this reaction a number of cytokines are produced, such as IL-
3, IL-4, and IL-5, which do not normally play a role in controlling VACV infection 
(61). The cellular signaling pathways triggered by these interleukins could be 
used as regulators of recombinase expression to develop a responsive logic-
gate.  
18 
 
 In these preliminary tests we were not able to demonstrate effective 
recombinase-based logical circuitry in VACV vectors. In all of our experiments 
wherein VACV-infected cells were transfected with our plasmids containing bxb1 
(pPL199, Figure 2D and pPL201, Figure 2F), we did not detect any green 
fluorescence, indicating a lack of Bxb1 activity in our VACV synthetic circuitry 
(Figures 3, 5). This may be for a number of reasons. While PhiC31 has been well 
characterized in eukaryotes (53), to our knowledge Bxb1 has not, and neither of 
them have previously been studied in cytoplasmic DNA viruses, so the protein 
product may be different than in prokaryotic cells. Even if the post-transcriptional 
and post-translational modifications are correct in VACV-infected cells, bxb1 may 
require codon optimization to be sufficiently expressed by VACV, however this is 
less likely due to the enzymatic nature of recombinases. It is also possible that a 
mutation occurred during our PCR cloning of bxb1, so there may be reason to 
repeat the cloning and reattempt this assay. However, since there are numerous 
other tools for altering DNA including other recombinases, transposases, and 
CRISPR-Cas systems (62) which could be used in logical VACV genetic circuitry 
(63), the need to invest significant resources beyond this in functionally 
expressing the bxb1 transgene is limited.  
 In all of our assays wherein VACV-infected cells were transfected with our 
plasmids containing phiC31 (pPL198, Figure 2C and pPL200, Figure 2E), both 
with and without inducer, we did not detect any red fluorescence but we did 
observe green fluorescence similar to the levels of the transfection control 
(Figure 3, 6). This suggests that our PhiC31-based circuitry poses the opposite 
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problem as it appears that the recombinase was active in every transfected cell 
regardless of the repressor system and absence of inducer. It is also possible 
that somehow the recombinase was expressed during cloning, prior to our 
transient expression assay, inverting the target promoter and causing all of our 
cells transfected with plasmids pPL198 and pPL200 to express green 
irresponsive to PhiC31 expression. This direction of the promoter in the final 
transfer vector will need to be verified by sequencing, possibly in conjunction with 
the parental vector pPL196 for comparison. If this is the case, then measures will 
be necessary to inhibit expression of this gene during cloning, even though it is 
downstream of a VACV promoter, not a bacterial one.  
 These results present the need for new controls to better verify that 
promoter inversion has occurred within the infection/transfection assay. Now that 
we know the fluorescence reporter genes on these plasmids work, in future 
experiments one could use the parental vectors, which lack recombinase genes, 
as negative controls to verify that red fluorescent reporter is expressed in the 
absence of recombinase. These or another DsRed plasmid should also be used 
as a control for comparison of DsRed expression during imaging. Finally, the 
best method to demonstrate promoter inversion would be to sequence the 
plasmid before the infection/transfection assay, and then collect, PCR, and 
sequence the plasmid DNA from wells in which green fluorescence was detected 
to compare the sequences and confirm inversion.  
The possibility that PhiC31 is highly active in VACV-infected cells also 
warrants discussion. In this study we used the lac and tet repressors because 
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they had been thoroughly characterized previously in recombinant VACVs. 
However, these systems are prone to “leaky” expression, and since even one 
molecule of recombinase is theoretically sufficient to permanently alter the target 
sequence, a tighter method of gene regulation may be necessary. One possibility 
may simply be to decrease the strength of the promoter upstream of the 
recombinase. Moss et al. characterized the strength of many natural VACV 
promoters (64) and our lab recently developed a series of weakened P11 
promoters (by systematically deviating from the consensus sequence) including 
the “P5” we used in pPL198-pPL201. Perhaps using an even weaker promoter 
may increase repressibility of recombinase expression.  
Based on the uncontrolled high efficiency of inversion exhibited by phiC31 
transfected cells, it may be more practical to implement a system which better 
inhibits gene expression, rather than being less capable of gene expression. 
Many genetic engineers control recombinases expression using “riboregulators”. 
Riboregulators are microRNAs (miRNAs) that post-transcriptionally repress the 
expression of a transgene that has been tagged with a 5’-complimentary 
sequence, allowing the miRNA to anneal to the transcript and form a secondary 
structure blocking the ribosomal binding domain (RBD) and preventing 
translation (65). Isaacs et al. originally developed both cis-repressor and trans-
activator systems using these molecules, and they have since been 
demonstrated to have great utility as regulators in genetic switchboards (66, 67).  
Characterization of these riboregulators in VACV synthetic circuitry may be an 
important next step in the development of recombinase-based VACV vectors, as 
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well as useful for gene regulation in VACV vectors in general.  Ultimately, in 
order to produce recombinant VACVs containing this sort of logical circuitry, we 
will face another hurdle in making sure that no undesired recombinase 
expression and activity occur during purification and amplification, further 
increasing the need for a much stricter mechanism for control of gene 
expression.  
We believe that we have developed a transient expression system for 
testing the functionality of recombinases and corresponding regulators of gene 
expression in VACV. Although we did not succeed in demonstrating inducible-
recombinase logic in VACV vectors, we did elucidate the problems that must be 
overcome in order to successfully develop this technology. Establishment of just 
two recombinases functional in VACV synthetic circuitry as well as an adequate 
regulatory system for the expression of these genes would allow for the 
implementation of binary logic gates in VACV vectors with tremendous potential 
for medical and research applications.   
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Figures 
 
 
 
Figure 1. Recombinase test vector concept. To test the functionality and 
repressibility of recombinases in VACV synthetic circuitry, we developed constructs that 
constitutively express a repressor (TetR or LacI, here “Rep”), which in the absence of 
the inducer binds to an operator, blocking transcription of the recombinase. In the 
presence of inducer (yellow squares), a conformational change occurs in the repressor 
protein, releasing it from the operator, permitting transcription of the recombinase. This 
catalyzes the inversion of a promoter, switching fluorescence reporter expression from 
red to green.  
29 
 
 
30 
 
Figure 2. Recombinase test plasmid maps. Plasmid vector backbones pPL189 
(A) and pPL190 (B) were synthesized by DNA 2.0 with a high-copy E. coli origin 
of replication and kanamycin resistance gene. EGFP, DsRed, repressors, and 
recombinases were cloned into backbones to produce recombinase test 
plasmids pPL198 (C) pPL199 (D) pPL200 (E) and pPL201 (F) for use in transient 
expression assays.  
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Figure 3. Initial test of logical circuits transient expression assay.  
Representative images of our pilot transient expression assay. BS-C-1 cells were 
infected with WR at an MOI of 1 and after 1 hour overlaid with complete DME 
supplemented with 2.5% FBS, with or without 1mg/ml doxycycline or 1mM IPTG 
and transfected with pPL198, pPL199. Wells were imaged using FITC (Green) 
and Texas Red (Red) fluorescent filters, and brightfield (BF) after 24 (A) and 48 
(B) hours p.t. As a transfection control, an uninfected monolayer was transfected 
with a plasmid coding for EGFP under a constitutive CMV promoter (C).  
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Figure 4. Repressibility of EGFP expression in vP11IRG-infected HeLa-S3 
cells. HeLa-S3 cells were infected with vP11IRG at an MOI of 1 and overlaid 
with 1 mg/ml Dox. Wells were imaged using FITC (Green) and Texas Red (Red) 
fluorescent filters, and brightfield (BF) after 24 (A), 48 (B), 72 (C) and 96 (D) 
hours p.t.  
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Figure 5. Expression of PhiC31 under Tet and Lac repressor systems. 
HeLa-S3 cells were infected with WR for 24 hours, overlaid with or without 
1mg/ml Dox or 1mM IPTG and transfected with pPL198 (A) and pPL200 (B). In 
order to pre-express TetR or LacI in transfected cells, we repeated this assay 
using cells infected with vS22 for pPL198 (C) and vP11IRG for pPL200 (D). 
Images shown are representative of 72 hours p.t. and taken using brightfield 
(BF), FITC (Green), or Texas Red (Red) fluorescent filters. 
40 
 
 
41 
 
 
 
 
 
42 
 
Figure 6. Expression of Bxb1 under Tet and Lac repressor systems.  
HeLa-S3 cells were infected with WR for 24 hours, overlaid with or without 
1mg/ml Dox or 1mM IPTG and transfected with pPL199 (A) and pPL200 (B). In 
order to pre-express TetR or LacI in transfected cells, we repeated this assay 
using cells infected with vS22 for pPL200 (C) and vP11IRG for pPL199 (D). 
Images shown are representative of 72 hours p.t. and taken using brightfield 
(BF), FITC (Green), or Texas Red (Red) fluorescent filters. 
